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Gastric cancer is the most common malignancy and the incidence is steadily increasing in Korea. The principal treatment modality for 
gastric cancer is surgical extirpation of tumor along with draining lymph nodes. Gastrectomy with D2 lymph node dissection has been 
well established as a standard of surgery and improved the survival of gastric cancer patients. Recently, technological advances are 
drastically reshaping the landscape of surgical treatment of gastric cancer. One of the most notable trends is that minimal access surgery 
becomes dominating the treatment of early stage diseases. For advanced diseases, the standard access surgery is considered a reference 
treatment. Although there is a pilot study underway to evaluate the feasibility of the application of minimal access surgery to advanced 
gastric cancer (AGC), the evidence for oncological safety is not yet provided sufficiently. Based on the recent randomized controlled trials, 
the extent of surgery for AGC has re-defined as para-aortic lymph node dissection dose not add any survival benefit while increasing sur-
gery-related morbidities. In addition, it is now accepted as a standard operation omitting unnecessary procedures such as splenectomy 
and/or distal pancreatectomy for prophylactic lymph node dissection. Conceptual and technical innovation has contributed to decreasing 
morbidity and mortality without impairing oncological safety. All these recent advances in the field of gastric cancer surgery would be 
concluded in maximizing therapeutic index for gastric cancer while improving quality of life.
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Introduction
Although the incidence of gastric cancer is decreasing world-
wide, it is the most common cancer in Korea where the incidence 
is steadily increasing.(1,2) In Korea, malignancy is the leading cause 
of death and gastric cancer is the third site of cancer mortality.(1,2) 
The survival rate of gastric cancer has increased, from over 40% 
in 1990s to more than 60% in the early 2000s, indicating that there 
was notable progress in the field of gastric cancer diagnosis and 
treatment.(1) 
The Information Committee of the Korean Gastric Cancer 
Association has performed nationwide survey to investigate the 
chronological changes and clinicopathological features of gastric 
cancer. The demographics and characteristics of patients with gas-
tric cancer in 2000s compared to 1990s have changed substantially 
in that there are increase of older patients and early cancer propor-
tions potentially due to the general population aging and height-
ened awareness of the checkup program, respectively. In addition, 
there was a trend of rise of upper gastric cancer and the number of 
patients with higher body mass index (BMI).(3,4)
All these changes and the progresses in the field of surgical 
treatment resulted in reshaping the landscape of surgical treatment 
of gastric cancer. In this review, we will discuss the recent trend, 
emerging concerns and future perspectives of gastric cancer treat-
ment in Korea focusing on operative surgery. 
Subject
The current standard treatment for operable gastric cancer is 
gastrectomy with D2 lymph node dissection which is a well-es-
tablished practice in Korea as well as in Japan.  The morbidity and 
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mortality rates of this reference procedure is about 17~20% and 
0.6~0.8%, respectively in Korea and Japan.(5,6) In two randomized 
controlled western studies, the morbidity was more than 40% and 
mortality was more than 10% in D2/D3 lymph node dissection. 
Moreover, because D2 gastrectomy showed no survival benefit over 
D1 gastrectomy, most western surgeons have been performed D1 
dissection.(7,8)
Before minimal invasive access surgery has emerged, open 
surgery was a standard way to reach peritoneal cavity. After 2000s, 
minimal invasive techniques have been applied pushfully for pa-
tients with early gastric cancer (EGC) and the proportion of these 
techniques are increasing. In the fields of minimal invasive concept 
are endoscopic resection, laparoscopic surgery, robotic surgery, and 
sentinel lymph node detection. However, the fundamental prin-
ciple that the oncological outcome and safety of minimally invasive 
techniques is comparable to the conventional method should be 
strictly followed. 
Treatment of Early Gastric Cancer
1. Endoscopic resection  
Endoscopic mucosal resection (EMR) is a treatment option 
for early gastric cancer with extremely low possibility of lymph 
node metastasis. The conventional worldwide indications of EMR 
are differentiated adenocarcinoma, a lesion ＜2 cm in diameter, 
no ulceration within the tumor, and no lymphovascular involve-
ment. Recently, due to the advances in endoscopic instrumentation 
and techniques, endoscopic submucosal dissection (ESD) became 
a main method of endoscopic treatment of early gastric cancer. 
ESD can achieve direct dissection of the submucosa without the 
limitation of tumor size. The large scaled multicenter trial in Korea 
showed the efficacy and safety of ESD, 95.3% of en-bloc resection 
and acceptable rate of complications (bleeding 15.6%, perforation 
1%).(9) Considering the benefits of ESD in minimizing the amount 
of invasive procedure, it has the potential to extend its indication. 
Many studies have been carried out to evaluate the risk of lymph 
node metastasis in submucosal or undifferentiated early gastric 
cancers to establish the most appropriate treatment strategy. Gotoda 
et al.(10) demonstrated that the subgroup of patients with a size less 
than 3 cm, well differentiated histology, no lymphovascular inva-
sion, and submucosal invasion depth of less than 500 μm showed 
no lymph node metastasis. They also showed there were no posi-
tive lymph nodes in EGC with undifferentiated lesions, no ulcer-
ation, and less than 2 cm. In Korea, there were some reports for 
subgroups of undifferentiated type EGC without lymph node me-
tastasis which has a potential to extend the indication of endoscopic 
treatment.(11,12) However, because the number of patients included 
in these criteria is small, the oncological safety of extended ap-
plication of ESD remains to be a matter of problem. Therefore, the 
standard treatment in EGC which are not included in conventional 
EMR criteria is still a surgical resection with appropriate lymph 
node dissection in Korea.(13)  
2. Rapidly developing surgical treatment 
One of the most notable trends is that minimal access surgery 
(MAS) becomes dominating the treatment of early stage diseases. 
Given that the equivalent procedures as standard surgery are de-
livered, the method of minimal invasive surgery would provide the 
comparable oncological outcomes in theory. With this premise, 
minimally invasive surgery (MIS) is now regarded as a viable alter-
native to standard access surgery for early gastric cancer. Moreover, 
the cosmetic advantage provided by the MIS/MAS is attractive to 
the patients, although this is way overly represented to the public. 
Laparoscopy-assisted gastrectomy is representative procedure 
of MIS and accepted as a safe and feasible surgical procedure for 
early gastric cancer. The number of laparoscopy-assisted gastrec-
tomy cases has increased rapidly for several years and more than 
3,000 cases of laparoscopy-assisted gastrectomy were performed in 
Korea in 2009. The indication for laparoscopy-assisted gastrectomy 
has been limited to early gastric cancer, which are less likely to ac-
company lymph node metastasis due to the concern for incomplete 
lymph node dissection and the lack of long-term outcome results. 
Korean Laparoscopic Gastrointestinal Surgery Study (KLASS) 
group published several multicenter large-scale retrospective results 
of laparoscopy-assisted gastrectomy.(14-16) In those studies, lapa-
roscopy-assisted gastrectomy showed similar long-term oncologic 
outcomes. The morbidity and mortality were similar to open sur-
gery. In early gastric cancer, the application of laparoscopic surgery 
will be increasing in the future. 
Robot surgery was invented to improve the difficulty and un-
comfortability of laparoscopic surgery. In Korea, robot-assisted 
gastrectomy was rapidly adapted by experienced laparoscopic sur-
geons and until now in 20 institutes, about 30 robot systems have 
been installed.(17) There are several benefits for surgeons in robotic 
surgery, such as 3-D visualization, freedom of intraabdominal mo-
tion by EndoWrist, comfortable surgeon’s position. They seem to 
be substantial for better and stable surgical circumstance and de-
veloping surgical techniques. Robot-assisted gastrectomy is a safe 
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procedure comparable to laparoscopic surgery. Considering high 
cost of patients or insurance pays, however, the efforts to identify 
patients’ merits should be sought. In addition, the long-term out-
come of robotic surgery should be evaluated. 
As a function-preserving procedure, there have been many re-
ports for pylorus-preserving gastrectomy (PPG) in Japan, but it has 
been performed limitedly in Korea. Park et al. reported that PPG 
has advantages over conventional distal gastrectomy with Billroth 
I anastomosis in gastric emptying, bile reflux, and gallstone.(18) 
However, the number of PPG is extremely limited, about 0.26 %, 
and the data is not enough in Korea.(3,4)
Proximal gastrectomy is a surgical option for EGC located at up-
per third of the stomach. The several reconstruction methods have 
been introduced, but the optimal method after gastrectomy remains 
controversial. In Korea, gastric tube esophagogastrostomy is mainly 
used because it is simple and fast and surgeons appear to be less 
favorable to jejunal or jejunal pouch interposition methods.(19,20) 
A large volume center reported that proximal gastrectomy was 
associated with a markedly higher rate of complications such as 
anastomotic stenosis and reflux esophagitis and to provide no benefit 
in terms of postoperative weight loss compared to total gastrectomy 
despite the surgical safety and curability were similar.(19) Therefore, 
proximal gastrectomy is not performed widely (1.1%) and total gas-
trectomy may be preferable in proximal EGC in Korea yet.(3,4)
Sentinel lymph node navigation surgery is a new paradigm shift 
in gastric cancer treatment. Sentinel lymph node is the first sites of 
metastasis through lymphatic drainage pathway from the primary 
tumor and it is a well established in breast cancer and melanoma. 
In gastric cancer, several surgeons in Japan performed many stud-
ies to develop surgical strategy based on sentinel lymph node status 
and the concept of lymphatic basin dissection and modified gastric 
resection for early gastric cancer without sentinel lymph node me-
tastasis is appealing. However, skip metastasis and false negative 
rate are critical points for using it in clinical practice.(21)
3. Efforts for renovating current practices 
As surgeons as well as patients have been interested in the pa-
tients’ satisfaction and better life after surgery, the necessity of pro-
cedures afflicting patients was thought earnestly. Nasogastric tube 
insertion was a common practice in abdominal surgery including 
gastric surgery, because some surgeons believed that anastomotic 
leakage, intraluminal bleeding, or aspiration pneumonia would be 
aggravated or detected too late without nasogastric decompression.
(22) However, a prospective study showed that gastric cancer sur-
gery can be performed safely without nasogastric decompression 
and this uncomfortable and unpleasant procedure is not applied 
to patients any more in many hospitals in Korea.(22) In line with 
this thinking, we found that prophylactic drain placement would 
not offer additional benefit for patients undergoing gastric cancer 
surgery with standard lymph node dissection.(23) These data might 
contribute to mitigating inconvenience of gastric cancer patients by 
leaving out unnecessary procedures. Epidural or intravenous an-
algesia for postoperative pain relief also help patients tolerate well 
after surgery. 
Surgical Treatment of Advanced 
Gastric Cancer
Conventional open surgery is the common approach method 
for advanced gastric cancer. Although the extent of lymph node 
dissection is controversial between eastern and western studies, 
radical gastrectomy with D2 lymph node dissection has been ac-
cepted as a standard procedure for advanced gastric cancer (AGC) 
in Korea and Japan.(24-26) Recently, with advances in technique 
and surgeon experience, the extended application of laparoscopy-
assisted gastrectomy for patients with advanced gastric cancer has 
been tried by several experienced surgeons. In several studies, 
the long-term outcomes after laparoscopy-assisted gastrectomy 
for advanced gastric cancer were comparable to open surgery. 
However, these retrospective studies had small number of patients 
with selection bias.(27,28) The technical and oncological safety of 
D2 lymphadenectomy by minimally invasive approach should be 
proven. Therefore, multicenter prospective study will be undergoing 
in Korea.
The demand for better quality of lifes changes surgical proce-
dures in detail achieving both of oncological safety and better qual-
ity of life. In these view, prophylactic splenectomy is not justified 
any more in Korea, which was a matter of debate in the past. Some 
authors showed that splenectomy for hilar lymph node dissection 
did not achieve oncological benefit even in locally advanced proxi-
mal gastric cancer.(29,30) A randomized clinical trial performed 
by several Korean surgeons showed splenectomy had no survival 
benefit in patients with metastatic lymph nodes at the hilum of the 
spleen.(31) Splenectomy for splenic hilar node dissection is not 
generally advised in Korea now.  
Para-aortic lymph node dissection is also no longer performed 
for treatment of gastric cancer. In several randomized studies com-
paring D2 and D2+para-aortic lymph node dissection performed 
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in Japan, D2+para-aortic lymph node dissection did not improve 
survival rate but it increased postoperative complications.(5,32-34)  
Recently, there was a discussion for the oncological benefit and 
the necessity of lymph node dissection along the superior mes-
enteric vein (no.14v). Lymph node no.14v is included in the D2 
lymph node dissection, but not in the D1+β lymph node dissection 
for treatment of distal gastric cancer.(35) The clinical significance 
of lymph node no.14v metastasis was evaluated in a large-scaled 
Japanese study, and the prognostic impact of 14v lymph node 
metastasis seems to be strong.(36) The authors suggested that the 
prognosis of patients with 14v metastasis was similar to those with 
systemic metastasis and only some patients had a chance to be 
cured by 14v dissection. In a retrospective Korean study, authors 
suggested a subgroup of gastric cancer getting merits from 14v 
dissection.(37) There is no western study for lymph node no.14v 
metastasis or dissection and this issue seems not to be appealing 
to western surgeons. Although randomized controlled study could 
clarify the clinical impact of 14v dissection, it is difficult to make 
progress the study in Korea due to patients consent. After all, lymph 
node no. 14v will be excluded from the extent of conventional D2 
lymph node dissection. 
Concluding Remark
The unshakable principle in surgical oncology is to deliver the 
curative surgery with the intent to improve the survival of cancer 
patients. Although this principle in gastric cancer treatment remains 
unchanged, the way of delivering this principle, making R0 resec-
tion, has drastically changed over the last decade in Korea. There is 
little evidence to indicate that current technological innovations in 
surgical treatment of gastric cancer have been the product of bio-
logical principle. Rather, advances in technical engineering research 
and the resulting empiricism have brought new technical innova-
tions to the clinical practice without noticeable resistance. Indeed, it 
is also recognized that even in the US, the early evolution of cancer 
surgery has been influenced by surgical technique and equipment 
innovations to a greater extent than by comprehension of the biol-
ogy of cancer. Although current and future technological develop-
ments will continue to play a major role in the surgical treatment of 
gastric cancer, it needs to be stressed that the clinical and basic re-
search should also be in parallel which dictates the future of gastric 
cancer and, ultimately, the fate of surgery. 
Regardless, the current status and the main stream trend is 
that minimally invasive procedures are generally accepted in early 
gastric cancer treatment, while conventional access gastrectomy 
with D2 lymph node dissection is regarded as a standard surgical 
treatment in advanced gastric cancer. Recently, KLASS-02 trial 
(laparoscopy vs conventional access) is conceived and now under-
going to evaluate the oncological safety and quality of life (QoL) in 
advanced cancer patients treated with laparoscopy-assisted surgery. 
Although this trial would be one of the milestones in clinical trials 
for gastric cancer surgical treatment, it raises some controversies 
among some physicians and investigators. The prognosis of ad-
vanced stage diseases still needs to be improved. Unlike contem-
porary oncological trials in which the newer drugs are assessed for 
efficacy in prolonging the survival of AGC patients, most surgical 
trials in these days are clinging to the QoL of patients: even in pa-
tients with advanced diseases. 
Although this would be a matter of viewpoint of many sur-
geons, we may need to reflect on ourselves and steer the right 
direction for further progress in surgical treatment of gastric can-
cer. It is foreseeable that studies for evaluating oncological safety 
and extending indication of minimal invasive techniques will be 
undergoing. Regardless, to improve the survival of gastric cancer, 
multimodal treatment including effective new agents in adjuvant or 
neoadjuvant setting should be more sought in parallel with current 
trends in surgical treatment of advanced cancer than now.     
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